TRG-120

TRG-120 is an investigational therapeutic candidate developed by Trigone Pharma for the treatment of overactive bladder (OAB). It is designed to alleviate symptoms such as urinary urgency and increased urination frequency. Although specific molecular targets have not been publicly disclosed, the drug likely utilizes Trigone Pharma's proprietary sustained-release intravesical delivery system. This technology involves a liquid formulation that transforms into a soft solid mass upon contact with urine, facilitating the prolonged release of active ingredients directly within the bladder over several days or weeks, thereby improving patient compliance and therapeutic efficacy compared to traditional oral or immediate-release treatments.